Table 3.

Univariate regression analysis. Association of baseline variables with the decrease in calcium concentration from before to after 1 month.

Characteristic	Estimation of partial regression coefficient	95 % CI	P	Standardized β
Age, years	0.019	0.003 to 0.035	0.02⁎	0.343
Sex	−0.018	−0.320 to 0.283	0.90	−0.018
BMI, kg/m2	0.015	−0.019 to 0.049	0.38	0.135
Albumin, g/dL	−0.250	−0.598 to −0.098	0.15	−0.213
Creatinine, mg/dL	−0.092	−0.904 to 0.720	0.76	−0.034
Calcium, mg/dL	0.289	0.084 to 0.495	0.007⁎	0.390
ALP, U/L	−0.0001	−0.001 to 0.001	0.84	−0.033
TRACP-5b, mU/dL	0.0001	−0.001 to 0.001	0.87	0.025
P1NP, ng/mL	−0.001	−0.005 to 0.002	0.35	−0.111
Presence of prior anti-osteoporosis medication, n	−0.056	−0.177 to 0.064	0.35	−0.140
With vitamin D supplementation, n	−0.008	−0.132 to 0.116	0.90	−0.020
With Calcium supplementation, n	−0.112	−0.411 to 0.187	0.45	−0.112
Baseline percentage of YAM at lumbar spine, %	−0.006	−0.015 to 0.004	0.23	−0.177
Baseline percentage of YAM at femoral neck, %	−0.008	−0.017 to 0.0003	0.06	−0.279
Baseline percentage of YAM at total femur, %	−0.008	−0.017 to 0.001	0.09	−0.265

ALP, alkaline phosphatase; BMI, body mass index; CI, confidence interval; P1NP, procollagen type 1 amino-terminal propeptide; TRACP-5b, tartrate-resistant acid phosphatase 5b; YAM young adult mean.

^⁎P < 0.05.